Incorporated in 2005 and headquartered in Hackensack, New Jersey, Amorcyte, Inc. is a development stage cellular therapies company focused on developing cell therapeutics for cardiovascular disease.

Our lead product, AMR-001 is an autologous stem cell product for the treatment of damaged heart muscle following acute myocardial infarction (AMI).

Amorcyte is a company with a corporate structure that is designed to minimize costs, maximize return on investment, and minimize the risks of product and corporate development, while maximizing the potential for speedy product approval.